1. Guidelines on non-muscle invasive bladder cancer Ta, T1 and CIS;Babjuk,2018
2. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 1.1, 2016, AWMF-Registrierungsnummer 032/038O. Available at: https://www.awmf.org/. Accessed: Aug 7, 2019.
3. Hall MC, Chang SS, Dalbagni GT, Pruthi RS, Schellhammer PF, Seigne JD, et al. Guideline for the management of nonmuscle invasive bladder cancer: stages Ta, T1 and Tis: update (2014), Available at: https://www.auanet.org/education/guidelines/bladder-cancer.cfm. Accessed: Aug 7, 2019.
4. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy;Holmäng;J Urol,2001
5. Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer;Hernandez;Urol Oncol,2016